Hain Celestial Group, Inc. — Form 10-Q Summary
Reporting period: First quarter of fiscal 2015, the three months ended September 30, 2014. Hain manufactures and sells organic and natural food, beverage, and personal care products. Unless otherwise stated, financial amounts below are in millions.
Financial results
| Metric | Q1 FY2015 | Q1 FY2014 | Change |
|---|---|---|---|
| Net sales | $631.3 | $477.5 | +32.2% |
| Gross profit / margin | $125.8 / 19.9% | $119.1 / 24.9% | Margin down 5.0 percentage points |
| Operating income / margin | $28.8 / 4.6% | $39.8 / 8.3% | Income down 27.5% |
| Net income | $18.9 | $27.7 | Down 31.8% |
| Diluted EPS | $0.37 | $0.57 | Down $0.20 |
| Operating cash flow | $2.6 | $53.6 | Down $51.0 |
| Operating free cash flow | $(10.6) | $41.3 | Down $51.9 |
Sales growth primarily reflected acquisitions of HPPC, Rudi’s, and Tilda, which together contributed $131.6 million in the quarter, including growth under Hain’s ownership. Foreign exchange added $8.8 million to sales. The nut butter recall reduced sales by $10.4 million through returns.
Gross margin was pressured by the nut butter recall, higher input costs, UK factory start-up costs, a European non-dairy beverage withdrawal, and the acquired businesses’ differing margin profiles. Recall-related costs reduced gross margin by about 290 basis points. SG&A rose 23.6% to $90.9 million, but declined as a share of sales to 14.4% from 15.4%.
Cash, debt, and liquidity
- Cash and cash equivalents were $92.7 million at September 30, 2014, down $31.1 million from June 30.
- Working capital was $413.1 million, up $33.7 million from fiscal year-end; receivables and inventories increased, principally in connection with HPPC and business growth.
- Total debt was $887.4 million, including $634.5 million under the revolving credit agreement, $150.0 million in senior notes, and Tilda and other borrowings. Debt increased from $867.9 million at June 30.
- The revolving facility is $850 million and expires in August 2017. The company reported $634.5 million outstanding; the filing does not state remaining availability as a clear value.
- Operating cash flow was affected by working-capital needs, seasonal Tilda inventory, and the recall. Capital expenditures were $13.3 million; management expected fiscal 2015 capital spending of approximately $45 million.
- Management said cash on hand, projected operating cash flow, and credit-facility availability should fund ordinary working capital, expected capital spending, and other cash needs for at least the next 12 months.
Material changes, outlook, and risks
- HPPC acquisition: On July 17, 2014, Hain acquired the remaining 51.3% of HPPC for $20.3 million cash and $19.7 million in stock, making it wholly owned. HPPC reported quarterly sales of $70.7 million and operating income of $3.8 million. Hain also recorded a $5.3 million non-taxable gain from remeasuring its pre-existing interest.
- Nut butter recall: The voluntary recall announced August 19 led to $22.8 million of pre-tax costs in the quarter, in addition to $6.0 million recorded in the prior fiscal fourth quarter. Hain said up to a further $7.0 million of pre-tax costs could be recorded, excluding insurance recoveries, and estimated about $0.8 million of additional transportation and storage costs during the remainder of fiscal 2015. The matter remained under discussion with the FDA.
- Other operating items: Hain recorded $2.7 million of UK factory start-up costs and $1.9 million of charges related to a non-dairy beverage withdrawal in Europe. Net income also included foreign currency losses, partly offset by the HPPC remeasurement gain.
- Management outlook: Hain cited continued exposure to volatile commodity and energy costs, higher input costs, global economic and political uncertainty, foreign exchange, acquisition integration, consumer demand, competition, and product recall or regulatory risks. It described plans to mitigate cost increases through efficiency, procurement initiatives, and pricing. The filing discusses risks to achieving fiscal 2015 sales and diluted EPS guidance but does not provide clear numerical guidance values in the text supplied.
- Other notable items: Foreign currency translation reduced other comprehensive income by $59.6 million in the quarter. A proposed 2-for-1 stock split, subject to shareholder approval of an increase in authorized shares, was announced after quarter-end. The company reported effective disclosure controls and no material change in internal control over financial reporting.
Key facts for investors to verify
- Whether recall costs, insurance recoveries, and FDA resolution differ from management’s estimates, including the potential additional costs disclosed.
- Whether acquired businesses—particularly HPPC and Tilda—deliver expected growth and margins, and how integration affects results.
- Whether working-capital requirements, seasonal inventory, and capital spending improve enough to restore cash generation.
- Debt levels, revolving-credit availability, and compliance with the credit agreement’s financial covenants.
- Any quantified fiscal 2015 sales and diluted EPS guidance, as numerical targets are not clear in the supplied filing text.
- Shareholder approval and implementation details for the proposed stock split.